GLP-1 Revolution
by Amaltash Advisors LLC
$18.56
-13.35% past month
Nov 16, 2026
$18.57-7.15%
Comparable listed companies in Pharmaceutical Preparations fell 3.83% on average, with 5 of 6 falling and none rising . The company's 7.15% decline was larger than the cohort average and came alongside that broad weakness .
Nov 13, 2026
$20.00+0.81%
Nov 12, 2026
$19.84-5.30%
Comparable pharmaceutical preparations companies fell 2.32% on average, with 5 of 6 declining . The stock's 5.30% drop came alongside that sector weakness and was larger than the cohort average .
Nov 11, 2026
$20.95-3.59%
Comparable Pharmaceutical Preparations companies were essentially flat, moving -0.02% on average, with 3 of 6 falling and 2 rising . The company's 3.59% decline was therefore not shared by the sector .
Nov 10, 2026
$21.73+1.49%
GPCR rose 1.49% while comparable pharmaceutical preparations companies fell 1.82% on average, with 5 of 6 declining . The gain ran against the direction of the cohort.
Nov 9, 2026
$21.41+5.21%
Comparable Pharmaceutical Preparations companies rose 4.98% on average, with 4 of 6 advancing . GPCR's 5.21% gain came alongside that cohort-wide rise.
Nov 6, 2026
$20.35+6.66%
Comparable pharmaceutical preparations companies rose 1.62% on average, with 5 of 6 higher . GPCR's 6.66% gain was therefore larger than the cohort's move. Volume was 1.6x its trailing 20-session average, and the session ranged from 18.70 to 21.31 .
Closing prices for GPCR. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, Structure Therapeutics Inc. is 80.2% below its 52-week high. Its largest decline in the period shown was -81.0% (Oct 31, 2023 to Apr 8, 2025).
As of Nov 16, 2026, Structure Therapeutics Inc. closed 80.2% below its 52-week closing high, set on Jan 21, 2026.
Structure Therapeutics Inc. fell 81.0% from Oct 31, 2023 to Apr 8, 2025, close to close, the largest decline in daily data since Feb 3, 2023. It closed back above that high on Jan 13, 2026.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Feb 3, 2023 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in Structure Therapeutics Inc. (GPCR) in Feb 2023, at the Feb 28, 2023 close, would be worth about $727 today, based on the Nov 16, 2026 close — a loss of $273 (-27.3%), dividends not included. Along the way it fell as much as 81.0% from a high, between Oct 31, 2023 and Apr 8, 2025.
Return calculator
Worth today, at the Nov 16, 2026 close
$3,159
-$2,241 · -41.5%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of GPCR's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell GPCR.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 3 years that's 720 coffees, or $3,600.
The same $100 a month put into GPCR since November 2023 would be worth $2,001 today.
This time, the coffee was the better buy.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | GPCR price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $35.81 | $519 | $5,186 | -48.1% |
| 3 years | Nov 30, 2023 | $55.69 | $333 | $3,335 | -66.7% |
| Since Feb 2023 | Feb 28, 2023 | $25.56 | $727 | $7,265 | -27.3% |
$10,000 invested in Structure Therapeutics Inc. (GPCR) at the Feb 28, 2023 close would have been worth about $7,265 at the Nov 16, 2026 close — a loss of $2,735 (-27.3%), dividends not included.
GPCR closed at $25.56 on Feb 28, 2023 (split-adjusted). It closed at $18.57 on Nov 16, 2026.
Putting $100 into GPCR at each month-end close from Feb 28, 2023 — 45 purchases, $4,500 in total — would have been worth about $2,505 at the Nov 16, 2026 close: a loss of $1,995 (-44.3%), dividends not included.
GPCR closed at $18.57 on Nov 16, 2026. A year earlier it closed at $36.82 on Nov 14, 2025, so it is down 49.6% over that year. Its highest close in the year to Nov 16, 2026 was $93.79 on Jan 21, 2026, and its lowest was $18.57 on Nov 16, 2026. These are split-adjusted closing prices; dividends are not included.
GPCR last closed at $18.57 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $36.82 on Nov 14, 2025 to $18.57 on Nov 16, 2026, it was down 49.6%. These are split-adjusted closing prices; dividends are not included.
As of Nov 16, 2026, Structure Therapeutics Inc. had a market value (market cap) of about $1.4 billion.
Structure Therapeutics develops medicines taken by mouth for weight loss and other long-term illnesses.
We do not tell anyone whether to buy or sell GPCR, and past results do not predict future results. Its largest fall from a high since Feb 3, 2023 was 81.0%, from $74.30 on Oct 31, 2023 to $14.15 on Apr 8, 2025. A single stock can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of GPCR's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell GPCR.
Try the full investment calculatorThese strategies on Amaltash hold GPCR today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC
by Amaltash Advisors LLC
This strategy bets on the booming weight-loss and metabolic health revolution — and it goes far beyond just the blockbuster drug makers you've heard about on the news. It builds a diversified basket across the entire ecosystem: companies developing next-generation obesity and diabetes treatments, the diagnostic labs helping doctors identify and monitor patients, the device makers tracking metabolic health, the clinics and care delivery platforms scaling treatment access, and even the insurers reshaping how metabolic disease is covered and reimbursed. The strategy focuses exclusively on companies that have already shown sustained upward price momentum over recent years — it's not trying to pick speculative moonshots, but rather ride names that the market has already started rewarding. The basket rotates and rebalances to keep exposure fresh, leaning into the strongest performers while trimming names that lose their footing. It's long-only and growth-oriented, meaning it profits when these companies rise in value — it does not short or hedge. The personality is opportunistic but not reckless: a built-in drawdown guardrail is designed to protect the portfolio if the sector hits a rough patch, targeting a maximum loss limit so a bad quarter doesn't wipe out a good year. Imagine this scenario: A major insurer announces it will cover GLP-1 treatments broadly. Drug makers surge, but so do the glucose monitors, the telehealth obesity clinics, and the cardiac device companies treating downstream complications. This strategy is already holding across all of those layers — capturing the wave rather than just one drop of it.
View strategy →